secwatch.observer — SEC 8-K summary
======================================

Issuer:     DELCATH SYSTEMS, INC. (DCTH)
CIK:        0000872912
Form:       8-K
Filed at:   2025-05-08T23:59:59+00:00
Accession:  0001628280-25-023470
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Delcath Q1 revenue surges to $19.8M, posts net income of $1.1M vs loss a year ago
--------------------------------------------------------------------------------

- Total revenue $19.8M (vs $3.1M Q1 2024); HEPZATO KIT sales $18.0M, CHEMOSAT $1.8M.
- Net income $1.1M vs net loss of $11.1M in prior-year quarter; gross margin 86%.
- Non-GAAP adjusted EBITDA $7.6M vs loss of $7.3M in Q1 2024.
- Cash and investments $58.9M, no debt; exercise of Series F warrants added $16.2M.
- 19 active U.S. centers; FDA cleared IND for phase 2 HEPZATO in metastatic breast cancer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/872912/000162828025023470/0001628280-25-023470-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/872912/000162828025023470/dcth-20250508.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-023470

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer